Novo Nordisk shares fall as obesity pipeline faces investor scrutiny
LONDON/COPENHAGEN — Shares in Novo Nordisk fell as much as 3.5 per cent on Monday after detailed trial data on its experimental obesity drug CagriSema fueled investor concerns about its competitiveness against rival Eli Lilly's pipeline.
Novo on Sunday said full results from two late-stage trials of CagriSema, one in people with obesity or overweight, the other in overweight type 2 diabetics, showed mainly mild-to-moderate side effects and positive outcomes on blood sugar.
But, as analysts had predicted ahead of the data release, investors remained skeptical.
Jefferies called the updates 'incremental' and flagged concerns over tolerability, as CagriSema caused slightly more nausea than both Novo's blockbuster obesity injection Wegovy and Lilly's rival therapy Zepbound.
The drug is not expected to launch until early 2027, 'a long-time interval for investors,' Novo and Lilly shareholder Markus Manns told Reuters.
Manns said sentiment in Lilly had been buoyed by data it also presented at the annual meeting of the American Diabetes Association in Chicago over the weekend that showed no safety issues in a mid-stage trial of its oral weight-loss candidate orforglipron in people with diabetes.
Late-stage obesity data for orforglipron are due in the third quarter.
'Novo's status has clearly changed from being the obesity leader to a fast follower,' Manns said.
CagriSema is key to Novo's efforts to compete with Lilly in the obesity market, which analysts estimate could top $150 billion annually by 2030.
Novo had billed CagriSema as a more potent successor to Wegovy, but late-stage headline trial results published in December 2024 fell short of market hopes, showing 22.7 per cent average weight loss over 68 weeks - below the company's 25 per cent target.
That sent shares plunging, wiping as much as $125 billion off its market value.
Last month, Novo ousted its CEO Lars Fruergaard Jorgensen amid concerns it was losing its first-mover advantage in the obesity drug race. One of the reasons cited for Jorgensen's removal was the share price decline.
Shares, which have slumped some 55 per cent since a June 2024 peak, are up about eight per cent since his departure was announced on May 16.
(Reporting by Maggie Fick and Stine Jacobsen; Editing by Jan Harvey)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
J.S. Held, Together with the Women's Engineering Society and UNESCO, Celebrate Women in Engineering
JERICHO, N.Y., June 23, 2025 /CNW/ -- Global consulting firm J.S. Held joins the Women's Engineering Society and the United Nations Educational, Scientific, and Cultural Organization (UNESCO) in celebrating International Women in Engineering Day (INWED). INWED provides an important "platform to showcase successes and achievements of female engineers" and, in 2025, celebrates under the theme Together We Engineer. Together We Engineer perfectly embodies the practice of engineering by more than 100 J.S. Held female engineers across ten countries. A collaborative collection of female experts who apply their engineering expertise to complex financial, technical, and scientific matters, helping clients proactively manage risk and respond to complex, contentious, and often catastrophic situations. Meet the J.S. Held Experts In the spirit of the 2025 Women in Engineering theme, #TogetherWeEngineer, J.S. Held is proud to highlight the work of a few of the firm's engineering experts: A data scientist working from India leverages her expertise in programming languages and database systems to analyze financial, operational, and transactional data, delivering insights that support both proactive risk management and reactive crisis response. Her work is integral to helping organizations mitigate the impact of misconduct and economic crime by applying technology and data science. A forensic investigations expert in Phoenix, Arizona, who applies her structural engineering and construction management background to conduct forensic investigations. An oil & gas expert working from the United Arab Emirates applies her experience as a project and cost engineer in the international oil & gas industry to her work, providing contractual analysis and quantum support on various contentious and non-contentious matters on projects spanning multiple sectors and jurisdictions, and authoring reports in the Arabic language for use in litigation proceedings. A digital transformation expert leverages her professional experience in SaaS products (web and mobile) in corporate and startup environments to support successful digital transformations for contracts and claims management, providing valuable data analysis for mid/long-term strategies and supporting the implementation of digital tools. A mechanical engineer applies expertise developed at the National Highway Traffic Safety Administration (NHTSA), where she led federal research on crash test dummy biofidelity and human injury risk evaluation in postures associated with autonomous vehicles, to her work in accident reconstruction. A London-based construction dispute expert applies her professional experience in architectural practices in Malaysia, the Philippines, and Singapore, along with her expertise in all stages of the construction process, to large-scale construction disputes in the UK and overseas by conducting research, analysis of technical design and specifications, and site investigations. Multidimensional Engineering-Informed Experts Benefit J.S. Held Clients Deep engineering expertise permeates the global organization. Multidisciplinary experts across J.S. Held combine engineering expertise with core specializations, including: Accident Reconstruction Builder's Risk Consulting Building Consulting Construction Advisory Construction Project Support Services Data Science Digital Investigations & Discovery Environmental, Health & Safety Forensic Architecture Global Investigations Health Sciences Human Factors Consulting Information Technology Strategy Advisory Surety Consulting Explore the expertise across J.S. Held by visiting Technology-enabled Expertise at J.S. Held Women across J.S. Held develop innovative technologies to deliver more effective and efficient client solutions. Multidisciplinary consulting experts are supported by in-house testing laboratories, investigative experts, and industry-leading forensic analysts. J.S. Held Commitment to Professional Development J.S. Held fosters an environment where women with engineering and other technical expertise – one of the firm's core specialties – are empowered to grow, lead, and make a meaningful impact in the industries and communities J.S. Held serves. Marjan Panah, Chief People Officer, observes, "What makes J.S. Held stand out is the breadth of expertise and diversity of our people. We leverage our different backgrounds, experiences, and skill sets to deliver unique value to our clients across a wide range of matters and geographies. Our leaders and communities ensure team members feel welcomed, respected, and appreciated." Join the J.S. Held Team J.S. Held is actively recruiting engineering experts across the global office network. Join a team of more than 1,500 professionals who serve organizations across six continents, including: 84% of the Global 200 Law Firms 75% of the Forbes Top 20 Insurance Companies 90% of the NAIC top 50 Property & Casualty Insurers 71% of the Fortune 100 Companies. Visit to learn more about opportunities to apply engineering expertise to positions in the Asia-Pacific region, Canada, Europe, South America, and the United States. About J.S. Held J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations. Verdantix, in their Green Quadrant: Enterprise Risk Management Consulting Services (2025) report, benchmarks 15 of the most prominent enterprise risk management (ERM) advisors, identifying global consulting firm J.S. Held among the leading companies based on capabilities and momentum J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice. Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC. All rights reserved.
Globe and Mail
2 hours ago
- Globe and Mail
Scott Barbrack On Risk, Resilience, And Why London's Entrepreneurs Need Strategic Support Now
In a world of uncertainty, Barbrack's journey shows how adaptability, timing, and support systems are key to survival—and success In a powerful new interview titled How Wall Street Lessons Help Scott Barbrack Navigate Business Risk — and Why It Matters in London, veteran investor and entrepreneur Scott Barbrack offers timely insights into the universal need for strategic resilience in business—especially in today's unpredictable economic climate. Drawing on his three-decade career spanning high-stakes finance, hospitality, and fashion, Barbrack's reflections highlight a deeper issue: the urgent need for support systems and adaptable thinking for startups and small businesses navigating volatility, particularly in dense urban centres like London. 'You've got seconds to make a call,' Barbrack says. 'If you're slow, the market—or the customer—moves on without you.' His comment applies beyond the trading floor. In London, where over 1 million small businesses make up 99.9% of the city's business population, startup survival has become increasingly precarious. According to the UK's Office for National Statistics, nearly 60% of new businesses fail within three years. Barbrack believes many of these failures aren't due to bad ideas—but to a lack of preparation and guidance. 'If you don't know your downside, you don't belong in the deal,' he says. 'That's not about being cynical. That's about being ready.' In the interview, Barbrack recalls his move from finance into the hospitality industry, becoming a partner in The Lion, a popular New York City restaurant. He notes the striking parallels: tight margins, quick decision-making, and rapidly shifting customer expectations. 'Everything could change in a single night,' he explains. 'A bad review, staff shortages, supplier delays—just like a sudden shift in market sentiment. It's all about reacting without panic.' Barbrack also discusses his early investment in Pretty Green, a UK-based fashion brand. It was a bet on brand identity and cultural resonance, not just spreadsheets. 'You ride the wave, but you've got to know when to exit too,' he says. His takeaway is clear: successful entrepreneurs—whether in London or New York—must balance gut instinct with real strategy, and perhaps more importantly, must not go it alone. 'Behind every business decision I've made, there's been a team, a network, a circle of people I trust,' Barbrack adds. 'In finance, it's your network. In restaurants, it's your staff. In fashion, it's your customers. No matter the industry, people are the real asset.' Call to action: Support small businesses, entrepreneurs, and mentorship networks Barbrack's story isn't just a reflection on past success—it's a rallying cry. He urges policymakers, communities, and individuals to invest time, mentorship, and infrastructure into supporting entrepreneurs, especially those navigating change. 'There's no shortage of ideas,' he says. 'What we need are more people willing to share what they've learned, to provide that bridge for someone else starting out.' If you're reading this, consider reaching out to a small business in your area, offering mentorship, or joining a local startup incubator. As Scott Barbrack reminds us: 'The more we normalise uncertainty, the more we empower people to face it—and thrive.' About Scott Barbrack Scott Barbrack is an investor and entrepreneur based in New York and New Jersey. With more than 30 years of experience in interest rate derivatives, hospitality, and brand investing, he brings a unique perspective on risk, timing, and strategic growth. He is a supporter of education, athletics, and professional mentorship. To read the full interview, click here. Contact: info@ Media Contact Contact Person: Scott Barbrack Email: Send Email Country: United States Website:
Globe and Mail
4 hours ago
- Globe and Mail
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and uncertainty around the talc lawsuits, among others. In addition, broader market uncertainties and a volatile macroeconomic environment have muted economic growth. However, J&J has some unique strengths, including continued strength in its Innovative Medicine unit, new drug launches, a robust pipeline, and steady revenue and EPS growth. Let's understand the company's strengths and weaknesses to better analyze how to play J&J stock amid the recent price uptick. J&J's Diversified Business Model Johnson & Johnson's biggest strength lies in its diversified business model. It operates through pharmaceuticals and medical device divisions. It has more than 275 subsidiaries, indicating that the business is extremely well-diversified. This diversification helps withstand economic cycles more effectively. J&J has 26 platforms with annual sales exceeding $1 billion. Meanwhile, it has one of the largest R&D budgets among pharma companies. J&J separated its Consumer Health business into a newly listed company called Kenvue KVUE in 2023. The separation of Kenvue has allowed J&J to focus on its core pharmaceutical and medical device business. JNJ's Innovative Medicine Unit: A Bright Spot J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 4.4% in the first quarter of 2025 on an organic basis despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. In 2025, J&J expects growth in the Innovative Medicine segment in the face of Stelara biosimilar entrants to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J expects to generate more than $57 billion in sales in the Innovative Medicines segment in 2025. It anticipates the Innovative Medicine business to grow 5-7% from 2025 to 2030. Moreover, J&J believes 10 of its new Innovative Medicine products, including new cancer drugs like Talvey and Tecvayli, and pipeline candidates, like nipocalimab and icotrokinra (JNJ-2113), have the potential to deliver peak non-risk-adjusted operational sales of $5 billion. Nipocalimab was approved under the name Imaavy in April for treating generalized myasthenia gravis. Nipocalimab is in mid and late-stage development for several rare autoantibody-driven diseases. J&J believes nipocalimab has the potential to create a pipeline in a product. Patent Expiration of J&J's Blockbuster Drug Stelara & Other Headwinds J&J lost U.S. patent exclusivity of Stelara in 2025. The drug generated sales of $10.36 billion in 2024. The launch of generics is expected to significantly erode the drug's sales and hurt J&J's sales and profits in 2025. Stelara sales declined 33.7% in the first quarter of 2025. A biosimilar version of Stelara was launched in certain European markets for some indications in July 2024. Several biosimilar versions of Stelara are expected to be launched in the United States in 2025. Amgen AMGN launched the first Stelara biosimilar, Wezlana, in January 2025, while Teva Pharmaceutical Industries TEVA launched Selarsdi in February 2025. Both Amgen and Teva had entered into settlement agreements with J&J for their respective biosimilar launches. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases. In addition, sales in 2025 are likely to be hurt by the impact of the Medicare Part D redesign, mainly sales of drugs like Stelara, Tremfya, Erleada and pulmonary arterial hypertension (PAH) drugs. Slowing Sales in J&J's MedTech Segment Sales in J&J's MedTech business are facing continued headwinds in the Asia Pacific, specifically in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. J&J's Talc Suits Remain an Overhang J&J faces more than 62,000 lawsuits for its talc-based products, primarily baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. J&J insists that its talc-based products are safe and do not cause cancer. The company permanently discontinued the sales of its talc-based Johnson's Baby Powder. In April, a bankruptcy court in Texas rejected J&J's proposed bankruptcy plan to settle its talc lawsuits after a two-week trial in Houston. J&J will go back to the traditional tort system to fight the lawsuits individually with its bankruptcy strategy to settle the lawsuits failing for the third time. J&J Stock Price, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 5.3% in the year-to-date period against a 1.2% decline for the industry. The stock has also outperformed the sector and S&P 500 Index, as seen in the chart below. JNJ Stock Outperforms Industry, Sector & S&P 500 From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 13.9 forward earnings, lower than 14.82 for the industry. The stock is also trading below its five-year mean of 15.75. JNJ Stock Valuation The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. JNJ Estimate Movement Stay Invested in J&J Stock While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern. The Stelara patent cliff and the potential impact of Part D redesign will be significant headwinds in 2025. It remains to be seen how the company navigates them. The legal battle surrounding its talc lawsuits has created a bearish sentiment around the stock. However, J&J considers 2025 to be a 'catalyst year,' positioning the company for growth in the second half of the decade. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. While newly launched products should drive growth in the Innovative Medicines segment in the second half, the MedTech segment may benefit from new products and easier comps. J&J expects growth to accelerate from 2026 onward. The company has an interesting R&D pipeline that can generate innovative products and further drive its growth. J&J has been on an acquisition spree lately, with the latest acquisition of Intra-Cellular Therapies strengthening its presence in the neurological and psychiatric drug market. In April, J&J's board authorized a 4.8% increase in its quarterly dividend, marking the company's 63rd consecutive year of dividend increase. Those who already own this Zacks Rank #3 (Hold) company's shares may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges. The stock price appreciation this year indicates the stock is on the path to recovery. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Kenvue Inc. (KVUE): Free Stock Analysis Report
